PCSK9 inhibitors in the management of atherosclerotic cardiovascular disease: Current clinical trials and future directions

被引：0
|
作者：
Nie, Wenyi [1 ]
Yue, Yingbin [2 ,3 ]
Hu, Jingqing [1 ]
机构：
[1] Changchun Univ Chinese Med, Changchun 130117, Peoples R China
[2] Xinjiang Med Univ, Affiliated Hosp 1, Urumqi 830054, Peoples R China
[3] Xinjiang Med Univ, State Key Lab Pathogenesis, Prevent & Treatment High Incidence Dis Cent Asia, Urumqi 830054, Peoples R China
来源：
ATHEROSCLEROSIS | 2024年 / 399卷
基金：
国家重点研发计划;
关键词：
PCSK9; inhibitors; Clinical trial; Existing evidence; Future perspectives;
D O I：
10.1016/j.atherosclerosis.2024.119043
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Clinical Shortcuts: PCSK9 Inhibitors
    Steiner, S.
    Berent, R.
    Derfler, K.
    Sinzinger, H.
    Auer, J.
    JOURNAL FUR KARDIOLOGIE, 2016, 23 (1-2): : 30 - 34
  • [32] PCSK9 inhibitors - clinical applications
    Schmidli, Robert
    AUSTRALIAN PRESCRIBER, 2016, 39 (05) : 168 - 170
  • [33] Small molecules as inhibitors of PCSK9: Current status and future challenges
    Xu, Shengtao
    Luo, Shanshan
    Zhu, Zheying
    Xu, Jinyi
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 162 : 212 - 233
  • [34] PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics
    Do, Rose Q.
    Vogel, Robert A.
    Schwartz, Gregory G.
    CURRENT CARDIOLOGY REPORTS, 2013, 15 (03)
  • [35] PCSK9 Inhibitors and Cardiovascular Events Reply
    Sabatine, Marc S.
    Wasserman, Scott M.
    Stein, Evan A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (08): : 774 - 775
  • [36] PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics
    Rose Q. Do
    Robert A. Vogel
    Gregory G. Schwartz
    Current Cardiology Reports, 2013, 15
  • [37] PCSK9 inhibition, atherosclerotic cardiovascular disease, and health economics: Challenges at the crossroads
    Annemans, Lieven
    Stock, Jane K.
    Chapman, John
    JOURNAL OF CLINICAL LIPIDOLOGY, 2019, 13 (05) : 714 - 720
  • [38] PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
    Katzmann, Julius L.
    Gouni-Berthold, Ioanna
    Laufs, Ulrich
    FRONTIERS IN PHYSIOLOGY, 2020, 11
  • [39] Is loss of function of PCSK9 a key in the protection against atherosclerotic cardiovascular disease?
    Reuwer, AQ
    CLINICAL GENETICS, 2006, 70 (01) : 15 - 17
  • [40] Hyperlipidemia: Effective Disease Management With a Focus on PCSK9 Inhibitors
    Shaw, Paul B.
    AMERICAN JOURNAL OF MANAGED CARE, 2021, 27 (04): : S63 - S69
12345